271 related articles for article (PubMed ID: 24505474)
1. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
4. Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women.
Ngamkham J; Boonmark K; Phansri T
Asian Pac J Cancer Prev; 2016; 17(3):1129-34. PubMed ID: 27039737
[TBL] [Abstract][Full Text] [Related]
5. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.
Insinga RP; Liaw KL; Johnson LG; Madeleine MM
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1611-22. PubMed ID: 18628412
[TBL] [Abstract][Full Text] [Related]
7. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
Malinova M
Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
[TBL] [Abstract][Full Text] [Related]
8. Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study.
Bertoli HK; Thomsen LT; Iftner T; Dehlendorff C; Kjær SK
Gynecol Oncol; 2020 May; 157(2):456-462. PubMed ID: 32008794
[TBL] [Abstract][Full Text] [Related]
9. Cancers attributable to human papillomavirus infection.
Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
[TBL] [Abstract][Full Text] [Related]
10. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
11. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.
Garland SM; Joura EA; Ault KA; Bosch FX; Brown DR; Castellsagué X; Ferenczy A; Ferris DG; Giuliano AR; Hernandez-Avila M; Huh WK; Iversen OE; Kjaer SK; Kurman RJ; Luna J; Monsonego J; Muñoz N; Paavonen J; Pitisuttihum P; Ronnett BM; Steben M; Stoler MH; Wheeler CM; Wiley DJ; Perez G; Saah AJ; Luxembourg A; Li S; DiNubile MJ; Wagner M; Velicer C
Obstet Gynecol; 2018 Aug; 132(2):261-270. PubMed ID: 29995724
[TBL] [Abstract][Full Text] [Related]
12. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
13. The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
Lindquist S; Frederiksen K; Petersen LK; Kjær SK
Int J Cancer; 2024 Jul; 155(1):61-70. PubMed ID: 38418719
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
[TBL] [Abstract][Full Text] [Related]
15. Update of HPV-associated female genital cancers in the United States, 1999-2004.
Watson M; Saraiya M; Wu X
J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
[TBL] [Abstract][Full Text] [Related]
16. Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention.
Pearson JM; Feltman RS; Twiggs LB
Womens Health (Lond); 2008 Mar; 4(2):143-50. PubMed ID: 19072516
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
Mpunga T; Chantal Umulisa M; Tenet V; Rugwizangoga B; Milner DA; Munyanshongore C; Heideman DAM; Bleeker MCG; Tommasino M; Franceschi S; Baussano I; Gheit T; Sayinzoga F; Clifford GM
Int J Cancer; 2020 Mar; 146(6):1514-1522. PubMed ID: 31173641
[TBL] [Abstract][Full Text] [Related]
18. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
19. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
20. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
